Author,year | Study | Ethical approval | Sample Size | Gender (M/F) | Age, years | BMI(kg/m2) | Radiographic Classification (K-L) | Clinical Outcomes | Follow-up Periods | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PRP + HA | PRP | HA | PRP + HA | PRP | HA | PRP + HA | PRP | HA | PRP + HA | PRP | HA | ||||||
Michele Abate 2015 [17] | Co,R | Yes | 40 | 40 | – | 31/9 | 21/ 19 | – | 56.7± 11.2 | 60.9 ± 9 | – | 23.7 ± 2 | 24.1± 1.6 | – | II-III | VAS,AE | 6 ms |
Wenxing Yu 2018 [18] | RCT | Yes | 96 | 104 | 88 | 50/46 | 50/ 54 | 48/40 | 46.5± 7.5 | 46.2 ± 8.6 | 51.5 ± 9.3 | – | – | – | I,II,III,IV | WOMAC, AE | 12 ms |
Yanqing Guo 2016 [19] | Co,P | Yes | 63 | 63 | – | 18/45 | 12/ 51 | – | 61.2± 9.6 | 60.7 ± 10.1 | – | 24.2 ± 4.2 | 24.6± 3.9 | – | I,II,III | VAS,AE, WOMAC | 12 ms |
Quanwei Ding 2017 [20] | RCT | Yes | 20 | 27 | – | 2/18 | 8/ 19 | – | 56.75± 9.536 | 62.11 ± 12.5 | – | 24.31± 3.764 | 24.27 ± 3.636 | – | I,II,III | WOMAC, VAS, Lequesne scores | 6 ms |
Xin-liang Zhao 2018 [21] | RCT | Yes | 62 | 62 | – | 35/27 | 37/ 25 | – | 55.73 ± 7.18 | 56.32 ± 8.13 | – | – | – | – | – | VAS | 1 month |
Yanqing Guo 2018 [22] | RCT | Yes | 63 | 63 | – | 45/18 | 51/ 12 | – | 61 ± 10 | 61 ± 10 | – | 24 ± 4 | 24 ± 4 | – | I,II,III | VAS,AE | 12 ms |
Chenrong Ke 2016 [23] | RCT | Yes | 50 | 50 | 50 | 25/25 | 24/ 26 | 23/27 | 57.8 ± 6.9 | 59.3 ± 7.1 | 58.8 ± 6.4 | – | – | – | I,II,III,IV | Lequesne scores,AE | 12 ms |